---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-297131"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2022-12-02T23:59:59+00:00"
generated_at: "2026-06-21T10:30:00.912590+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Amgen confirms potential all-cash offer for Horizon Therapeutics

## Summary
- Amgen states any offer for Horizon will be solely in cash.
- No certainty that a formal offer will be made; further updates expected.
- Disclosure follows Horizon's Rule 2.4 announcement; made under Irish Takeover Rules.

## SEC filing metadata
- accession: 0001193125-22-297131
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2022-12-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000119312522297131/0001193125-22-297131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000119312522297131/d424230d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-297131
- JSON: https://secwatch.observer/filing/0001193125-22-297131.json
- Plain text: https://secwatch.observer/filing/0001193125-22-297131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.